1-14 of 14
Lu Tang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CAR-T Cell Antitumor Activity

Jianghua Wu, Wenjing Luo, Lu Tang, Zhaozhao Chen, Jie Zhou, Chenggong Li, Wei Xiong, Heng Mei, Yu Hu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2061.
https://doi.org/10.1182/blood-2023-181472
Published: 2023
Journal Articles

BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System

Wenjing Luo, Chenggong Li, Jianghua Wu, Yinqiang Zhang, Lu Tang, Mengyi Du, Xindi Wang, Wei Xiong, Haiming Kou, Cong Lu, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10294–10295.
https://doi.org/10.1182/blood-2022-170898
Published: 2022
Journal Articles

Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Yinqiang Zhang, Chenggong Li, Huiwen Jiang, Wenjing Luo, Mengyi Du, Fen Zhou, Lu Tang, Jianghua Wu, Qiuzhe Wei, Cong Lu, Haiming Kou, Di Wu, Chang Alex H, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4592–4594.
https://doi.org/10.1182/blood-2022-170819
Published: 2022
Journal Articles

Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy

Jianghua Wu, Lu Tang, Mengyi Du, Chenggong Li, Haiming Kou, Huiwen Jiang, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Danying Liao, Wei Xiong, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7384–7385.
https://doi.org/10.1182/blood-2022-166674
Published: 2022
Journal Articles

Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

Chenggong Li, Xindi Wang, Zhuolin Wu, Wenjing Luo, Yinqiang Zhang, Yun Kang, Jia Xu, Zhongpei Huang, Mengyi Du, Lu Tang, Jianghua Wu, Danying Liao, Haiming Kou, Cong Lu, Huiwen Jiang, Qiuzhe Wei, Sha Ke, Jing'e Zheng, Wei Xiong, Jun Deng, Yu Hu, Heng Mei
Journal: Blood
Blood (2022) 140 (Supplement 1): 4573–4574.
https://doi.org/10.1182/blood-2022-170686
Published: 2022
Journal Articles

Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL

Mengyi Du, Chenggong Li, Fen Zhou, Wenjing Luo, Yinqiang Zhang, Lu Tang, Jianghua Wu, Huiwen Jiang, Qiuzhe Wei, Haiming Kou, Cong Lu, Chunrui Li, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10321–10322.
https://doi.org/10.1182/blood-2022-168695
Published: 2022
Journal Articles

Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies

Heng Mei, Lu Tang, Huan Zhang, Fen Zhou, Mengyi Du, Jianghua Wu, Chenggong Li, Qiuzhe Wei, Wenjing Luo, Yinqiang Zhang, Xindi Wang, ZhaoZhao Chen, Jie Zhou, Zhuolin Wu, Zhongpei Huang, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 634–635.
https://doi.org/10.1182/blood-2022-168590
Published: 2022
Journal Articles

Timing of Tocilizumab and Corticosteroids Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Yinqiang Zhang, Heng Mei, Chenggong Li, Yingnan Li, Mengyi Du, Wenjing Luo, Lu Tang, Jianghua Wu, Linghui Xia, Yu Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 4832.
https://doi.org/10.1182/blood-2021-149135
Published: 2021
Journal Articles

Single-Cell Analyses Identify Transcriptional Characterizations of Subsets Associated with Efficacy and Toxicity for CAR-T Immunotherapy in B-ALL Patients

Mengyi Du, Heng Mei, Chenggong Li, Yinqiang Zhang, Lu Tang, Jianghua Wu, Haiming Kou, Yu Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 4815.
https://doi.org/10.1182/blood-2021-150216
Published: 2021
Journal Articles

Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Chenggong Li, Qi Chang, Jing Wang, Mengyi Du, Lin Liu, Haiming Kou, Cong Lu, Lu Tang, Jianghua Wu, Wenjing Luo, Yinqiang Zhang, Sha Ke, Jun Deng, Cheng Liu, Yu Hu, Heng Mei
Journal: Blood
Blood (2021) 138 (Supplement 1): 826.
https://doi.org/10.1182/blood-2021-152661
Published: 2021
Journal Articles

A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity

Jianghua Wu, Heng Mei, Jianwei Li, Jingpeng Zhang, Lu Tang, Mengyi Du, Fangting Li, Yu Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 3132.
https://doi.org/10.1182/blood-2021-149381
Published: 2021
Journal Articles

Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia

Lu Tang, Heng Mei, PhD MD, Yu Hu, MD PhD, Zhinan Yin, PhD MD, Huiwen Jiang, Chenggong Li, Min Xu
Journal: Blood
Blood (2019) 134 (Supplement_1): 1399.
https://doi.org/10.1182/blood-2019-130354
Published: 2019
Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin
Journal: Blood
Blood (2019) 134 (Supplement_1): 930.
https://doi.org/10.1182/blood-2019-130340
Published: 2019
Journal Articles

TXAS -deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death

I-Shing Yu, Shu-Rung Lin, Chin-Chin Huang, Hui-Yu Tseng, Pei-Hsing Huang, Guey-Yueh Shi, Hua-Lin Wu, Chi-Lu Tang, Pao-Hsien Chu, Lee-Ho Wang, Kenneth K. Wu, Shu-Wha Lin
Journal: Blood
Blood (2004) 104 (1): 135–142.
https://doi.org/10.1182/blood-2003-10-3661
Published: 2004